drugset / Trial / NCT00671736

Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis

NCT00671736 ↗

Phase 2 Completed 160 enrolled AOP Orphan Pharmaceuticals AG
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a dose-finding study for the investigational product Lancovutide (Moli1901) in the exploratory phase IIb to establish minimum effective dose, optimal dose, and maximum safe dose. Additionally, the tolerability of Moli1901 shall be investigated.

Timeline

Start
2007-10
Primary completion
2009-07
Completion
2009-07

Outcome

Missed primary endpoint

paper Lancovutide did not improve FEV1 percent predicted when compared to placebo (NCT00671736). PMID 32888826 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject LANCOVUTIDE Protein / enzyme biologic 2.5 mg Inhaled

Indications